ALLK - צמיחת מכירות משנה לשנה (TTM) allakos.com

Allakos Inc. (ALLK) TTM revenue growth year-over-year is driven by demand from patients with chronic allergies and support from insurance funds. Growth is fueled by unique antibodies against Siglec-8 receptors, which create significant pricing power. Stability is guaranteed by the neutral geopolitical status of biomedicine. The value of 0.00 serves as the current parameter value, capturing the existing trend on the chart.
פילוחי נתונים אנליטיים מרוכזים עבור Allakos Inc (ALLK)

The selection of high-quality issuers is based on the stability of financial metrics, where the 12-month year-over-year revenue growth rate offsets cyclical volatility by calculating the daily change in rolling annual income. For Allakos Inc. (ALLK), this indicator distinguishes random spikes from fundamental growth, confirming the commercial potential of the AK006 antibody development and the company's investment attractiveness for acquisition by a Big Pharma behemoth.